Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Between 21 and 70 years old.~* Documented to be HBsAg positive for ≥ 6 months.~* On any nucleos(t)ide analogue (lamivudine, adefovir, entecavir or tenofovir)for ≥ 1 year~* HBV DNA undetectable by RT PCR at screening~* Patient has agreed not to take any other investigational drug or systemic anti-viral, cytotoxic, corticosteroid, immunomodulatory agents or Chinese traditional remedies unless clinically indicated.~* Patient is able to give written consent prior to study start and to comply with the study requirements.~* Women of childbearing age must have a negative serum (ß-HCG) pregnancy test taken with 14 days of starting therapy~Exclusion Criteria:~* Evidence of decompensated liver disease or hepatocellular carcinoma.~* Have any of the following laboratory tests within 4 weeks of study entry:~* HIV antibody or HCV antibody or HDV antibody positivity~* Absolute neutrophil count \< 1.5 X 109/l or platelets \< 90 x 109/l or hemoglobin \< 13 g/dL for men or 12g/dL for women~* serum albumin \<35 g/l or serum bilirubin \> 30 mg/l~* creatinine \> 1.5 times upper limit of normal~* prothrombin time \> 1.5 times control, uncorrected by Vitamin K therapy.~* Any interferon, Immunomodulators, systemic cytotoxic agents, or systemic corticosteroids within 6 months before trial entry.~* Prolonged exposure to known hepatotoxins such as alcohol or drugs.~* History of clinically relevant psychiatric disease, seizures, central nervous system dysfunction, severe pre-existing cardiac, renal, hematological disease or medical illness that in the investigator's opinion might interfere with therapy.~* Malignant disease within 5 years of trial entry.~* Women who are pregnant and who are not practicing adequate birth control measures, or who are lactating

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Continued oral nucleos(t)ide therapy (Type: ACTIVE_COMPARATOR): Patients assigned to this arm will continue their nucleos(t) analogue
- Add on peg-interferon (Type: EXPERIMENTAL): Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
- switch to peg-interferon (Type: EXPERIMENTAL): Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).